semaglutide glp-1 ra | | Clinical Development Semaglutide changed the category. Tirzepatide

Biousse, V

Patients with certain genotypes may respond optimally at lower doses, while others require higher escalation

Clinical evidence shows that patients initiating therapy at 0.25 mg weekly often experience appetite suppression within days, leading to reduced calorie intake without conscious dietary restriction

Energy levels often improve as weight decreases and metabolic strain lessens, making exercise feel more sustainable

Bex M, Bouillon R: Growth hormone and bone health

But after shortages made that treatment harder to get, patients turned to other pharmaceuticals like Novo Nordisks Ozempic and Eli Lillys Mounjaro that are approved only for Type 2 diabetes